Melanoma & Skin Cancer

Dr. Sezar and Dr. Stratigos discuss the FDA approvals of cemiplimab-rwlc in advanced non–small cell lung cancer and advanced basal cell carcinoma.

Michael A. Davies, MD, PhD, discusses the potential utility of ERK inhibitors in melanoma.

Suthee Rapisuwon, MD, discusses the potential utility of toripalimab in melanoma subtypes.

Arsen Osipov, MD, discusses the role of combination immunotherapy across multiple tumor types.

Michael A. Davies, MD, PhD, discusses the management of patients with melanoma during the COVID-19 pandemic.

Suthee Rapisuwon, MD, discusses the utility of frontline immunotherapy vs targeted therapy in acral and mucosal melanoma.

The FDA has granted an Orphan Drug designation to the investigational tumor-infiltrating lymphocyte therapy ITIL-168 for the treatment of patients with stage IIB to IV melanoma.

The first patient with PD-1/PD-L1–refractory melanoma has been dosed in the phase 2 LUMINOS-102 trial, which will evaluate the safety and efficacy of PVSRIPO alone or in combination with a PD-1/PD-L1 inhibitor in this patient population.

Suthee Rapisuwon, MD, discusses the biologic differences between mucosal and cutaneous melanoma.

Darovasertib, both as a single agent and in combination with binimetinib, has demonstrated promising early activity in patients with metastatic uveal melanoma, according to preliminary data from an ongoing phase 1/2 trial.

Although anticancer therapies that leverage T cells have commanded the most attention in the immuno-oncology era of the past decade, strategies based on natural killer cells have recently emerged as attractive approaches.

Combining the 31-gene expression profile test with current American Joint Committee on Cancer staging guidelines may improve risk assessment in patients with cutaneous melanoma, as well as determine which patients could be candidates for more intense follow-up.

Chronic immune-related adverse effects arising from adjuvant anti–PD-1 therapy in patients with high-risk melanoma are more common than previously recognized, and often persisted with longer follow-up.

Single-agent pembrolizumab yielded robust antitumor activity in patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma.

The tumor-infiltrating lymphocyte therapy lifileucel was found to elicit durable responses in patients with advanced melanoma who were previously treated with an immune checkpoint inhibitor.

The addition of ipilimumab to nivolumab as an adjuvant treatment failed to improve relapse-free survival in the intent-to-treat and PD-L1 of less than 1% populations compared with nivolumab alone in patients with resected stage IIIB to D/IV melanoma.

Tebentafusp (IMCgp100) resulted in a highly significant and clinically meaningful improvement in overall survival when given as a frontline treatment in patients with metastatic uveal melanoma.

Douglas B. Johnson, MD, discusses the risks and benefits associated with anti–PD-1 therapy in patients with stage III resected melanoma.

HEPZATO KIT has demonstrated statistically significant benefit compared to best alternative care in patients with liver-dominant metastatic ocular melanoma, according to preliminary results from the phase 3 FOCUS trial.

Michael A. Davies, MD, PhD, discusses the potential role of novel BRAF inhibitors in treating patients with melanoma and brain metastases.

The combination of tilsotolimod plus ipilimumab failed to improve objective response rate over ipilimumab alone in patients with advanced melanoma who are refractory to a PD-1 inhibitor, missing the primary end point of the phase 2 ILLUMINATE-301 trial.

The FDA has granted an orphan drug designation to the orally bioavailable, highly-specific G protein-coupled estrogen receptor agonist LNS8801 for the treatment of patients with metastatic uveal melanoma.

The FDA has granted an orphan drug designation to cavrotolimod for the treatment of patients with Merkel cell carcinoma.

Michael B. Atkins, MD, discusses the efficacy of dabrafenib plus trametinib in patients with BRAF-mutated melanoma.

Neoantigen long peptide vaccines continued to show durable T-cell responses in patients with high-risk melanoma that persisted 4 years after initial vaccination.